BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
World Lung 2025 preview – late-breakers in focus
Summit and Nuvalent have scored prized plenary spots.
Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
